Confectionery makers continue to tap into consumer weight and health concerns in a bid to boost stagnant sales as UK confectioner Cadbury launches a new range of chocolate bars with under 99 calories.
White adolescent and African-American girls assimilate salt and calcium differently, say researchers, claiming this may explain why races have different rates of high blood pressure and osteoporosis.
While the low-carb fad wanes, new research suggests the higher the carbohydrate intake, the greater the risk an elder woman will develop cataracts.
Trans fatty acids could ?modestly? increase the risk of gallstone disease, say US researchers, providing yet more evidence to encourage food makers to remove these fats from food formulations.
A diet rich in milk does not increase the risk of heart disease and stroke as previously thought and may even be protective, concludes new research, reports Dominique Patton.
Grapefruit seed extract appears to help treat stomach ulcers, according to Polish researchers.
Experiments in mice show that an antiviral drug currently used against annual influenza strains also can suppress the deadly influenza virus that has spread from birds to humans, killing dozens of people in Vietnam, Cambodia and Thailand since early 2004. This study, the first published report conducted on oseltamivir against the H5N1 influenza strain circulating in Vietnam, found that the drug, sold commercially as Tamiflu, dramatically boosted the survival rate of infected mice.
Scientists supported by the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health, have added a key new piece to the puzzle of how tumor cells induce new blood vessels to form and fuel their abnormal growth, a well-known process called angiogenesis.
A stopwatch-sized device that uses electrical impulses to treat chronic depression won U.S. Food and Drug Administration approval.
Interleukin-2 (IL-2), an immune-boosting drug used experimentally in HIV therapy, greatly increases the lifespan of certain subsets of immune system T cells in some HIV-positive people who respond to this therapy, discovered researchers from the National Institutes of Health (NIH) Clinical Center and the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. A report describing the study, led by the Clinical Center?s Joseph A. Kovacs, M.D., appears online today in The Journal of Clinical Investigation.